Aclarubicin
Trials 15 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT04254640 Background | Mar 2021 → Jun 2023 | acute myeloid leukemia | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03045627 Comparator | Jan 2017 → Jan 2018 | acute myeloid leukemia | Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT03181815 Background | Jan 2016 → Dec 2019 | acute myeloid leukemia | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07541755 Background | May 2025 → Jan 2027 expected | T-cell acute lymphoblastic leukemia | Fujian Medical University Union Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05382390 Background | Jan 2022 → Jan 2024 | acute myeloid leukemia | Huihan Wang | Unknown | No outcome recorded |
| Phase 3 | NCT04716114 Comparator | Mar 2021 → Dec 2025 | acute myeloid leukemia | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05258799 Background | Jan 2022 → Jan 2024 | acute myeloid leukemia | Huihan Wang | Unknown | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aclarubicin | “Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm,...” PMID 32873343 ↗ Sep 202021“PD-1 inhibitor+venetoclax+Cytarabine+Aclarubicin+G-CSF regimen” NCT07541755 ↗ “homoharringtonine (HHT), cytarabine and aclarubicin (HAA)” NCT04716114 ↗ “A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9” NCT04168138 ↗ “low-dose cytarabine (ara-C) and aclarubicin (ACR)” NCT05382390 ↗ “Aclarubicin:10mg/d, d3\~d10, intravenous infusion” NCT04087967 ↗ “Aclarubicin:10mg/d, d4\~7, intravenous infusion” NCT06394011 ↗ “aclarubicin (14 mg/m2 daily, days 3-6)” NCT05258799 ↗ “Aclarubicin (Acla) 20mg/day, days 3-7” NCT05893472 ↗ “Aclarubicin 5mg/m²/day, D1-D4 (IV)” NCT04216355 ↗ “Aclarubicin :10mg/d, d3\~d10” NCT04446130 ↗ |
| Known as | Acla | “Aclarubicin (Acla) is an anthracycline antitumor drug and is a type II topoisomerase Inhibitor that prevents topoisomerase II from binding to DNA primarily by intercalating...” NCT05264883 ↗2“Aclarubicin (Acla) is an anthracycline anticancer drug.” NCT07535762 ↗ “Aclarubicin (Acla) 20mg/day, days 3-7” NCT05893472 ↗ |
| Known as | aclacinomycin | “Aclarubicin (aka aclacinomycin, aclacinomycin-A) is an anthracycline antibiotic isolated from Streptomyces galilaeus cultures.” NCT02723448 ↗ |
| Known as | aclacinomycin-A | “Aclarubicin (aka aclacinomycin, aclacinomycin-A) is an anthracycline antibiotic isolated from Streptomyces galilaeus cultures.” NCT02723448 ↗2“Aclarubicin, also known as aclacinomycin A, is an anthracycline type of antibiotic with significant anti-cancer properties.” NCT07486726 ↗ “Aclarubicin, also known as aclacinomycin A, is an anthracycline type of antibiotic with significant anti-cancer properties.” NCT07535710 ↗ |
| Known as | ACLARUBICIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL502620 ↗ |
| Known as | Aclarubicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL502620 ↗ |
| Known as | Aclarubicine | ChEMBL registry synonym — accepted as the source's own label CHEMBL502620 ↗ |
| Known as | ACR | “low-dose cytarabine (ara-C) and aclarubicin (ACR)” NCT05382390 ↗ |
| Known as | NSC-208734 | ChEMBL registry synonym — accepted as the source's own label CHEMBL502620 ↗ |
| Action | Inhibit | “Inhibiting OST with aclarubicin corrects these glycan and immune defects in mouse models and in patient-derived cells.” NCT02723448 ↗ |
| Modality | Small molecule | “is an anthracycline type of antibiotic” NCT07486726 ↗ |
| Route | Intravenous | “Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle.” NCT02723448 ↗ |